Efffect of clozapine and typical antipsychotics on P50 suppression in patients with schizophrenia

Efffect of clozapine and typical antipsychotics on P50 suppression in patients with schizophrenia

Saved in:

Bibliographic Details
Main Author:	Jefferson Becker
Format:	Article
Language:	English
Published:	Thieme Revinter Publicações 2003-06-01
Series:	Arquivos de Neuro-Psiquiatria
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2003000200036
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Use of third-generation antipsychotics in combination with clozapine in the treatment of resistant schizophrenia
by: A. R. Asadullin, et al.
Published: (2025-06-01)

Antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co-treatment
by: Jari Tiihonen, et al.
Published: (2012-01-01)

Following the Action of Atypical Antipsychotic Clozapine and Possible Prediction of Treatment Response in Schizophrenia
by: Mihai-Gabriel Năstase, et al.
Published: (2025-05-01)

Pattern of P50 suppression deficit in patients with epilepsy and individuals with schizophrenia
by: Jefferson Becker, et al.
Published: (2011-06-01)

Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-08-01)

The effect of clozapine on immune-related biomarkers in schizophrenia patients
by: Lu Shao, et al.
Published: (2024-11-01)

Predictors of clozapine concentration and psychiatric symptoms in patients with schizophrenia.
by: Sang-In Park, et al.
Published: (2025-01-01)

Treatment of Hypochondriasis in Two Schizophrenia Patients Using Clozapine
by: Antonio Tundo, et al.
Published: (2017-01-01)

Clozapine-Induced Rhabdomyolysis in a Patient With Paranoid Schizophrenia: A Case Study Highlighting the Importance of Vigilance in Antipsychotic Therapy and Recurrence During Re-Challenge
by: Nitish Jayanth Kumaraswamy, et al.
Published: (2025-06-01)

Evaluation of Typical Antipsychotic Augmentation with Citalopram in Reduction of Negative Symptoms in Inpatient Schizophrenia in Ahvaz Golestan Hospital
by: Masome Nazari Nasab, et al.
Published: (2012-09-01)

Monitoring of clozapine and norclozapine concentrations in schizophrenia treatment
by: N. V. Baymeeva, et al.
Published: (2018-02-01)

Repurposed Antipsychotics as Potential Anticancer Agents: Clozapine Efficacy and Dopaminergic Pathways in Neuroblastoma and Glioblastoma
by: Catarina Moura, et al.
Published: (2025-07-01)

Manipulation of Lipid Nanocapsules as an Efficient Intranasal Platform for Brain Deposition of Clozapine as an Antipsychotic Drug
by: Ahmed A. Katamesh, et al.
Published: (2024-11-01)

Factors Associated with Poor Response to Clozapine in Patients with Treatment-resistant Schizophrenia
by: Jaison George, et al.
Published: (2025-07-01)

Case Study – Restarting Clozapine in a Patient With Treatment Resistant Schizophrenia
by: Sabaritha Subramania Pillai, et al.
Published: (2025-06-01)

Managing Recurrent Clozapine-Induced Constipation in a Patient with Resistant Schizophrenia
by: Silviu Tomulescu, et al.
Published: (2021-01-01)

Osteoporosis Associated with Antipsychotic Treatment in Schizophrenia
by: Haishan Wu, et al.
Published: (2013-01-01)

The antipsychotics functional index (AFI) in schizophrenia
by: Gabriel-Cristian Marinescu, et al.
Published: (2025-07-01)

Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials
by: Georgia Salanti, et al.
Published: (2023-02-01)

Perspectives of clozapine-naïve outpatients with treatment-resistant schizophrenia on clozapine commencement: a mixed-methods convergent study
by: Jimmi Nielsen, et al.
Published: (2025-03-01)

COVID-19 disease outcomes in patients receiving clozapine versus other antipsychotics: a national study in Qatar
by: Dalia Albahari, et al.
Published: (2025-05-01)

Augmentation of Clozapine in Treatment Resistant Schizophrenia – Is There a Superior Strategy?
by: Priya Babla, et al.
Published: (2025-06-01)

The Prevalence of Tardive Dyskinesia In Patients With Schizophrenia Treated With Antipsychotics In Malaysia
by: Nedunjelian A, et al.
Published: (2025-03-01)

Study of factors associated with obesity in patients using antipsychotics in schizophrenia
by: Vishalakshi Patnam, et al.
Published: (2024-12-01)

Candidate genes of the development of antipsychotic-induced parkinsonism in patients with schizophrenia
by: E. E. Vaiman, et al.
Published: (2021-12-01)

Correction: The antipsychotics functional index (AFI) in schizophrenia
by: Gabriel-Cristian Marinescu, et al.
Published: (2025-07-01)

Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia
by: I. A. Vilyum, et al.
Published: (2018-05-01)

Higher clozapine concentration-to-dose ratios at week 1 after initiation are associated with increased risk of clozapine-associated fever in Japanese patients with schizophrenia
by: Yuki Kikuchi, et al.
Published: (2025-05-01)

Neuroleptic malignant syndrome and subsequent clozapine-withdrawal effects in a patient with refractory schizophrenia
by: Cheng M, et al.
Published: (2016-03-01)

Optimal Treatment of Magnetic Seizure Therapy (MST) in Patients with Clozapine-Resistant Schizophrenia (CRS)
by: Xiang Q, et al.
Published: (2025-03-01)

Reintroduction of Clozapine following Neuroleptic Malignant Syndrome in a Young Patient with Resistant Schizophrenia
by: Miriam Chandad, et al.
Published: (2024-01-01)

Prevalence of obsessive-compulsive symptoms in patients with schizophrenia treated with clozapine: a scoping review
by: Evelyn Moreno Tarazona, et al.
Published: (2025-01-01)

Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy
by: Dhandapani Nandakumar, et al.
Published: (2023-06-01)

Levothyroxine Augmentation in Clozapine Resistant Schizophrenia: A Case Report and Review
by: Ruohollah Seddigh, et al.
Published: (2015-01-01)

Comparative Evaluation of Typical Antipsychotic Haloperidol with Atypical Antipsychotics Olanzapine, Risperidone and Aripiprazole in the Treatment of Stable Schizophrenia in a Tertiary Care Teaching Hospital at Dehradun, Uttarakhand, India: A Randomised Clinical Trial
by: Subhash Vishal Garg, et al.
Published: (2025-04-01)

Sexual differences in the clinical features of antipsychotic-induced hyperprolactinemia in patients with schizophrenia
by: E. G. Kornetova, et al.
Published: (2019-10-01)

Comparative analysis of EEG in patients with schizophrenia receiving various atypical antipsychotics
by: S. A. Galkin, et al.
Published: (2024-04-01)

Deterioration of COVID-19 vaccine efficacy by antipsychotic medications in schizophrenia patients
by: Takashi Kusunoki, et al.
Published: (2025-05-01)

Predictors of relapse after discontinuing antipsychotics in patients with schizophrenia spectrum disorders
by: Ling Li, et al.
Published: (2025-03-01)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
by: Leonid Mikhaylovich Bardenshteyn, et al.
Published: (2010-06-01)